 FOSTER CITY, Calif., Jan. 12, 2023 GLOBE NEWSWIRE -- Terns Pharmaceuticals, Inc. Terns or the Company Nasdaq: TERN, a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, obesity and non-alcoholic steatohepatitis NASH, today announced that management will participate in a fireside chat at the B. Riley Securities 3rd Annual Oncology Conference on Wednesday, January 18, 2023 at 2:30 p.m. ET. 